- Home
- IRD vs ATRA Comparison
IRD vs ATRA Comparison
Compare IRD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- ATRA
- Stock Information
- Founded
- IRD 2018
- ATRA 2012
- Country
- IRD United States
- ATRA United States
- Employees
- IRD N/A
- ATRA N/A
- Industry
- IRD
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IRD
- ATRA Health Care
- Exchange
- IRD NYSE
- ATRA Nasdaq
- Market Cap
- IRD 59.1M
- ATRA 51.1M
- IPO Year
- IRD N/A
- ATRA 2014
- Fundamental
- Price
- IRD $1.18
- ATRA $11.58
- Analyst Decision
- IRD Strong Buy
- ATRA Strong Buy
- Analyst Count
- IRD 3
- ATRA 4
- Target Price
- IRD $6.33
- ATRA $20.00
- AVG Volume (30 Days)
- IRD 295.4K
- ATRA 60.7K
- Earning Date
- IRD 08-15-2025
- ATRA 08-11-2025
- Dividend Yield
- IRD N/A
- ATRA N/A
- EPS Growth
- IRD N/A
- ATRA N/A
- EPS
- IRD N/A
- ATRA N/A
- Revenue
- IRD $13,651,000.00
- ATRA $199,732,000.00
- Revenue This Year
- IRD $51.41
- ATRA N/A
- Revenue Next Year
- IRD $68.84
- ATRA N/A
- P/E Ratio
- IRD N/A
- ATRA N/A
- Revenue Growth
- IRD N/A
- ATRA 475.53
- 52 Week Low
- IRD $0.65
- ATRA $5.01
- 52 Week High
- IRD $2.09
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- ATRA 66.87
- Support Level
- IRD N/A
- ATRA $8.53
- Resistance Level
- IRD N/A
- ATRA $13.46
- Average True Range (ATR)
- IRD 0.00
- ATRA 0.96
- MACD
- IRD 0.00
- ATRA 0.28
- Stochastic Oscillator
- IRD 0.00
- ATRA 62.65
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).